Niowave announced today that it broke ground on a new $75 million production facility in Lansing, Michigan. The isotope manufacturing plant significantly expands the company’s manufacturing footprint and strengthens the domestic supply of Actinium‑225 (Ac‑225), a critical isotope used in next‑generation targeted cancer therapies. The isotope supports targeted cancer therapies designed to destroy cancer cells…